Search the Newsreel

NewMarket Corp (NEU) Risk Assessment: Volatility, Financial Risk & Investment Risk

NewMarket Corp (NEU) has a risk assessment score of 7.81, placing it 20th out of 65 in the Chemicals industry. The company's beta of 0.57 indicates lower volatility compared to the S&P 500. The article details various risk metrics including maximum drawdown, volatility, Sharpe …

Wacker Neuson SE Aktie News & Newsfeed

Neuphoria Therapeutics (NEUP) Gains Ground as Support Holds Above $3.70 - Jurik MA

SNP Schneider-Neureither & Partner SE gibt Ergebnisprognose für das Jahr 2026

Neuphoria Therapeutics (NEUP) Gains 3.55% as Stock Tests Key Resistance Near $4.14 - Stock Analysis

CTNM|Contineum Therapeutics Inc|Price:15.040|Chg%:-0.310

Renaissance Technologies LLC Has $21.21 Million Stock Position in NewMarket Corporation $NEU

NewMarket Corporation (NYSE: NEU) lifts Q2 profit, builds specialty materials

EQS-News: SNP Schneider-Neureither & Partner SE: SNP setzt sein starkes Wachstum fort und verzeichnet das beste zweite Quartal seiner Unternehmensgeschichte

Neuphoria Therapeutics Inc (NEUP) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Neuphoria Therapeutics Inc (NEUP), noting its current score of 1.18, ranking 321 out of 384 in the Biotechnology & Medical Research industry. The company's beta of 0.73 indicates it tends to underperform during rising markets but experiences …

Maxim Group Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Maintains Target Price $35

Maxim Group has reiterated its Buy rating for ProMIS Neurosciences (PMN.US) and maintained its price target of $35. This indicates continued confidence from the firm in the company's prospects.

Minerva Neurosciences Inc (NERV) Financial Health: Profitability & Balance Sheet Analysis

TradingKey assesses Minerva Neurosciences Inc. (NERV) with a financial score of 7.28, placing it 134th out of 384 in the Biotechnology & Medical Research industry, indicating robust financial status but low operating efficiency. The analysis highlights that key data for detailed metrics like cash …

JUNS|Jupiter Neurosciences Inc|Price:0.099|Chg%:-0.000

This article provides a comprehensive stock analysis of Jupiter Neurosciences Inc (JUNS) by TradingKey. It highlights the company's healthy fundamentals, high growth potential, and current fair valuation. Despite recent weak stock market performance, the company shows strong technicals and has a high institutional ownership.

NewMarket: Q2 Earnings Snapshot

NewMarket Corp. (NEU) reported its second-quarter earnings, showing a profit of $133.8 million, or $14.54 per share. The company, which specializes in petroleum additives and lubricants, posted revenues of $747.1 million for the period.

NewMarket reports Q2 2026: Net income $133.8M, EPS $14.54; H1 net income $251.8M, EPS $27.14

NewMarket (NEU) announced its second-quarter 2026 results, reporting net income of $133.8 million, or $14.54 per share, and first-half net income of $251.8 million, or $27.14 per share. Total net sales reached $747.1 million for Q2 2026 and $1.417 billion for the first half, …

NewMarket (NYSE: NEU) lifts Q2 2026 profit to $133.8 million

NewMarket Corporation reported increased profitability for Q2 and the first half of 2026, with Q2 net income rising to $133.8 million, or $14.54 per share. This improvement was driven by higher sales in both petroleum additives and specialty materials segments, along with operational efficiencies …

Scancell, Neuphoria Agree to All-Share Merger

Biotech companies Scancell Holdings Plc and Neuphoria Therapeutics Inc. have agreed to an all-share merger, leading to the combined entity listing on Nasdaq and an additional $89 million in financing. This merger aims to fund a crucial Phase 3 clinical trial for Scancell's melanoma …

Neumora Therapeutics, Inc. Revenue Breakdown – NASDAQ:NMRA

NERV|Minerva Neurosciences Inc|Price:4.080|Chg%:+0.110

Minerva Neurosciences Inc. (NERV) has a relatively healthy fundamental outlook with high growth potential, though its valuation is considered fair. Analysts have rated the stock as 'Hold' with a target price of $9.50, suggesting a potential upside of 138.69%. The company, a clinical-stage biopharmaceutical …

Neumora Therapeutics Inc. (NMRA) Q1 2026 Earnings: Narrower-Than-Expected Loss on Cost Discipline, Shares Slip - Margin Compression Risk

Neuronetics Inc (STIM) Institutional Confidence

Neuronetics Inc (STIM) exhibits an institutional shareholding score of 5.00, placing it 107th within the Healthcare Equipment & Supplies industry. The company's institutional shareholding proportion recently increased by 11.24% quarter-over-quarter to 68.80%. The largest institutional shareholder is Bill Nygren | OAKMX, holding 5.49K shares.

H.C. Wainwright reiterates Buy on NeuroPace stock after FDA feedback

H.C. Wainwright has reiterated a Buy rating and a $20.00 price target for NeuroPace Inc (NASDAQ:NPCE) despite the FDA not approving its Premarket Approval Supplement in its current form. The FDA is requesting additional clinical evidence but has provided a path forward for potential …

NeuroPace FDA Bid for Expanded Epilepsy Use Stalls as Agency Seeks More Data

NeuroPace's premarket approval supplement to expand the RNS System's use for idiopathic generalized epilepsy (IGE) has been deemed "not approvable" by the FDA, which is requesting more clinical evidence. The company plans to submit a Submission Issue Request to discuss its response with the …

HC Wainwright Reaffirms Buy Rating for NeuroPace (NASDAQ:NPCE)

HC Wainwright has reaffirmed its "Buy" rating for NeuroPace (NASDAQ:NPCE), setting a price target of $20.00, suggesting a 30.63% upside. NeuroPace exceeded quarterly earnings expectations, reporting a loss of $0.13 per share against an estimated $0.19 loss, and revenues of $22.0 million, slightly above …

Neumora Therapeutics (NMRA) Expected to Release Earnings on Wednesday

Neumora Therapeutics (NMRA) is projected to release its Q2 2026 earnings before market open on August 5th, with analysts anticipating a loss of $0.23 per share. The company previously exceeded estimates with a $0.30-per-share loss. Despite recent target price reductions, analysts maintain a "Moderate …

Clearpoint Neuro Inc (CLPT) Institutional Confidence

Clearpoint Neuro Inc (CLPT) has an institutional shareholding score of 5.00, ranking 107th in the Healthcare Equipment & Supplies industry. Institutional ownership increased by 23.25% quarter-over-quarter, with 52.78% of shares held by institutions. The largest institutional shareholder, Bill Nygren | OAKMX, holds 124.35K shares, …

Neuronetics Inc (STIM) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Neuronetics Inc (STIM), detailing its performance against the Healthcare Equipment & Supplies industry. It highlights the company's risk score of 2.08, ranking 160 out of 199 in its industry, and its beta of 1.07 suggesting higher volatility …

Neuronetics Inc (STIM) Financial Health: Profitability & Balance Sheet Analysis

This article analyzes the financial health of Neuronetics Inc (STIM), indicating a weak financial status with a score of 6.57 out of 10, ranking 149th in its industry. Despite this, the company showed a 7.75% year-over-year revenue increase and a 14.87% net profit increase …

Promis Neurosciences (NASDAQ:PMN) Upgraded at Chardan Capital

Promis Neurosciences $PMN Stock Holdings Boosted by Ally Bridge Group NY LLC

Yu Fan Buys New Stake in Promis Neurosciences $PMN

Aeroflex Neu Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

NeuroOne Medical Technologies Corp (NMTC) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for NeuroOne Medical Technologies Corp (NMTC), ranking it 157 out of 199 in the Healthcare Equipment & Supplies industry with a score of 2.21. It highlights NMTC's beta value of 0.53, indicating lower volatility compared to the S&P …

ProMIS Neurosciences (PMN) Surges 21.3% Pre-Market Ahead of Earnings; Valuation Reflects High Growth Expectations

ProMIS Neurosciences (PMN) experienced a 21.3% pre-market surge ahead of its earnings announcement, driven by investor optimism despite being a clinical-stage biotech with no current sales. The company's valuation is speculative, based on future growth potential in neurodegenerative disease therapeutics, rather than traditional financial …

Advising Nasdaq-listed Neuphoria Therapeutics Inc. on its USD250M merger with AIM-listed Scancell Holdings

Winston Taylor is advising Nasdaq-listed Neuphoria Therapeutics Inc. on its $250 million all-share merger with AIM-listed Scancell Holdings plc, which also involves an $89 million equity and debt financing package. This merger will enable the combined entity, operating under the Scancell name, to fund …

Neurocrine Biosciences Inc (NBIX) Financial Health: Profitability & Balance Sheet Analysis

Neurocrine Biosciences Inc (NBIX) currently holds a financial score of 8.50, placing it 50th out of 155 companies in the Pharmaceuticals industry, indicating stable financial health and high operating efficiency. The company reported a significant year-over-year revenue increase of 42.25% to $814.50 million and …